CSIMarket Company Name, Ticker, Customers, else..


Adma Biologics Inc  (NASDAQ: ADMA)
Other Ticker:  
 

Adma Biologics Inc

ADMA's Fundamental analysis



Looking into Adma Biologics Inc growth rates, revenue grew by 40.67 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 312

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 12.76 %

Adma Biologics Inc's net income grew by 51.1 % in first quarter of 2025 year on year, above company average,

• More on ADMA's Growth


Adma Biologics Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Adma Biologics Inc PEG ratio is at -0 Company is currently trading with Price to Cash flow multiple of 175.28 in trailing twelve-month period.
Company
19.54
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.49.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.


• More on ADMA's Valuation
 
 Total Debt (Millions $) 73
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,275,682
 Net Income/Employee (TTM) $ 598,790
 Receivable Turnover (TTM) 8.91
 Tangible Book Value (Per Share $) 1.51

Adma Biologics Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Adma Biologics Inc PEG ratio is at -0 Company is currently trading with Price to Cash flow multiple of 175.28 in trailing twelve-month period.
Company
19.54
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.49.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.

Adma Biologics Inc Price to Book Ratio is at 11.62 lower than Industry Avg. of 1869. and higher than S&P 500 Avg. of 0.01

• More on ADMA's Valuation

•  Market Capitalization (Millions $) 4,341
•  Shares Outstanding (Millions) 245
•  Employees 401
•  Revenues (TTM) (Millions $) 512
•  Net Income (TTM) (Millions $) 240
•  Cash Flow (TTM) (Millions $) 25
•  Capital Exp. (TTM) (Millions $) -12
•  Total Debt (Millions $) 73
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,275,682
•  Net Income/Employee(TTM) $ 598,790
•  Receivable Turnover Ratio (TTM) 8.91
•  Tangible Book Value (Per Share $) 1.51

•  Market Capitalization (Millions $) 4,341
•  Shares Outstanding (Millions) 245
•  Employees 401
•  Revenues (TTM) (Millions $) 512
•  Net Income (TTM) (Millions $) 240
•  Cash Flow (TTM) (Millions $) 25
•  Capital Exp. (TTM) (Millions $) -12


    ADMA's Profitability Comparisons
Adma Biologics Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 30.57 % from 40.43 % in IV. Quarter.

Adma Biologics Inc net profit margin of 23.58 % is currently ranking no. 12 in Biotechnology & Pharmaceuticals industry, ranking no. 45 in Healthcare sector and number 562 in S&P 500.


Profitability by Segment
Total 30.01 %



  Ratio
•   Capital Ratio (MRQ) 6.74
•  Total Debt to Equity (MRQ) 0.19
•  Tangible Leverage Ratio (MRQ) 0.34
•  Asset Turnover Ratio (TTM) 1.16
•  Inventory Turnover Ratio (TTM) 1.35



Adma Biologics Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 30.57 % from 40.43 % in IV. Quarter.

Adma Biologics Inc net profit margin of 23.58 % is currently ranking no. 12 in Biotechnology & Pharmaceuticals industry, ranking no. 45 in Healthcare sector and number 562 in S&P 500.

• More on ADMA's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com